A Novel Epigenetic Strategy to Treat Ewing Sarcoma

Mary Beckerle, PhD
Ralph E. and William T. Main Presidential Professor
CEO and Director, Huntsman Cancer Institute
The University of Utah

A team at Huntsman Cancer Institute that includes Mary Beckerle, PhD, Steve Lessnick, MD, PhD, Sunil Sharma, MD, and Alana Welm, PhD has received a $1.73 million grant from CureSearch to test a novel targeted treatment for Ewing sarcoma that hopefully will disrupt the cancer’s growth and spread.

Ewing sarcoma is the second most common bone cancer in children and is a challenging cancer to treat because it has typically metastasized , or spread, by the time it is diagnosed. Further, once cancer has spread, many patients relapse after their initial chemotherapy and surgery. It is widely known that Ewing sarcoma occurs because of a chromosomal abnormality that causes an atypical protein, known as EWS/FLI, to be present (also called expressed), and that when EWS/FLI is expressed, literally thousands of genes mutate, or change from their normal state.

Now, a team at the University of Utah’s Huntsman Cancer Institute led by Mary Beckerle PhD and including Steve Lessnick MD PhD, Sunil Sharma MD, and Alana Welm PhD has received a $1.73 million grant from CureSearch to test a novel targeted treatment for Ewing sarcoma that hopefully will disrupt the cancer’s growth and spread.

Read more…

Post a Comment

Your email is kept private. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>